Global Genitourinary Partnering Deal Trends, Players and Financials Directory 2014-2019

News provided by

Oct 24, 2019, 12:30 ET

DUBLIN, Oct. 24, 2019 /PRNewswire/ -- The "Global Genitourinary Partnering 2014-2019: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Genitourinary Partnering 2014 to 2019 provides the full collection of Genitourinary disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Genitourinary partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Genitourinary partnering agreement structure
Genitourinary partnering contract documents
Top Genitourinary deals by value
Most active Genitourinary dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genitourinary disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genitourinary deals.

The report presents financial deal terms values for Genitourinary deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genitourinary dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genitourinary dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genitourinary deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Genitourinary dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genitourinary deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genitourinary partnering deals by specific Genitourinary target announced since 2014. The chapter is organized by specific Genitourinary therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genitourinary partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genitourinary partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genitourinary technologies and products.

In Global Genitourinary Partnering 2014 to 2019, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Analyzing actual contract agreements allows assessment of the following:

What are the precise Genitourinary rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genitourinary dealmaking
2.1. Introduction
2.2. Genitourinary partnering over the years
2.3. Genitourinary partnering by deal type
2.4. Genitourinary partnering by industry sector
2.5. Genitourinary partnering by stage of development
2.6. Genitourinary partnering by technology type
2.7. Genitourinary partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genitourinary partnering
3.1. Introduction
3.2. Disclosed financials terms for Genitourinary partnering
3.3. Genitourinary partnering headline values
3.4. Genitourinary deal upfront payments
3.5. Genitourinary deal milestone payments
3.6. Genitourinary royalty rates

Chapter 4 - Leading Genitourinary deals and dealmakers
4.1. Introduction
4.2. Most active in Genitourinary partnering
4.3. List of most active dealmakers in Genitourinary
4.4. Top Genitourinary deals by value

Chapter 5 - Genitourinary contract document directory
5.1. Introduction
5.2. Genitourinary partnering deals where contract document available

Chapter 6 - Genitourinary dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Genitourinary therapeutic target

Appendices
Appendix 1 - Directory of Genitourinary deals by company A-Z 2014 to 2019
Appendix 2 - Directory of Genitourinary deals by deal type 2014 to 2019
Appendix 3 - Directory of Genitourinary deals by stage of development 2014 to 2019
Appendix 4 - Directory of Genitourinary deals by technology type 2014 to 2019

Companies Mentioned

A1M Pharma
Acerus
Aceto Corporation
Acon Labs
Acurx Pharmaceuticals
AEterna Zentaris
Aetna
Akebia Therapeutics
AKESOgen
Alivio Therapeutics
Allegis Holdings
Allergan
Alnylam Pharmaceuticals
AM-Pharma
American Diabetes Association
American Medical Systems
Amgen
Angion Biomedica
Anthem Bluecross
Anthera Pharmaceuticals
Applied Medical
Aquinox Pharmaceuticals
Arch Biopartners
Ardelyx
Arena Pharmaceuticals
Arkray USA
Arrevus
Ascend Therapeutics
Astellas Pharma
Astellas Pharma US
AstraZeneca
Astute Medical
Atara Biotherapeutics
Aytu BioScience
Aziyo Biologics
Baxter International
Beckman Coulter
Beijing Leadman Biochemistry
BioCad Holding
BioDerm
bioMerieux
BioPorto
BioSerenity
BioVectra
Boehringer Ingelheim
Boston Scientific
Bridge Medicines
Brigham and Women's Hospital
Caldera Pharmaceuticals
CamelBak
Cara Therapeutics
CARB-X
Cardio Renal Society of America
Casper Pharma
Celtic Biotech
ChemoCentryx
CJ Corp
Cleveland Clinic
Clinipace Worldwide
Codexis
Cogentix Medical
Collaborative Study Group
Columbia University
Control Flo Medical
Cook Biotech
Cook Medical
Corino Therapeutics
Covance
CrossBay Medical
Cryolife
Cumberland Pharmaceuticals
CytoSorbents
Dalton Pharma Services
DaVita HealthCare Partners
Debiotech
Degania Silicone
Dignify Therapeutics
DILIsym Services
Dimerix Biosciences
DiscoveryBioMed
Distal Access
Duchesnay
Ecole Polytechnique Federale de Lausanne
EDAP TMS
EirGen Pharma
Elexopharm
EMD Serono
Endo International
Epigen Biosciences
Erasmus University Medical Center
Everest Medicines
Evestra
Evotec
Fedora Pharmaceuticals
Ferring Pharmaceuticals
Fimbrion Therapeutics
FirstString Research
Fortress Biotech
Fosun Pharmaceutical
Fougera Pharmaceuticals
Foundation for International Urogynecological Assistance
Fred Hutchinson Cancer Research Center
French Investment Fund
Frenova Renal Research
Fresenius Medical Care
FSC Laboratories
Gebro Pharma
Gedeon Richter
Geisinger Medical Center
GeneNews
Genewiz
Genzyme
George Washington University
GlaxoSmithKline
Goldfinch Bio
Government of Canada
Hainan Sihuan Pharmaceutical
Hancock Jaffe Laboratories
Harvard Stem Cell Institute
Healthy.io
Helix BioPharma
HemoCleanse
Hitachi Medical Systems Europe
Humana
Hydra Biosciences
HydroCision
Icahn School of Medicine at Mount Sinai
Idera Pharmaceuticals
IDIBELL
ImpediMed
Imprimis Pharmaceuticals
Innovation Network Corporation
Innovative Diagnostic Laboratory
Innovus Pharmaceuticals
Invitae
InVivo
Ion Channel Innovations
Ionis Pharmaceuticals
Itochu
Janssen Research & Development
Japan Tobacco
Johns Hopkins University
Juventas Therapeutics
Karolinska Institute
Keryx Biopharmaceuticals
Kyorin Pharmaceutical
Kyowa Hakko Kirin
L&F Research
Laboratorios Q Pharma
La Jolla Pharmaceutical
Lavasta Pharma
LeMaitre Vascular
Lupus Foundation of America (LFA)
Luqa Pharmaceuticals
Mannin Research
Mar Cor Purification
Mariel Therapeutics
Massachusetts General Hospital
Mayo Clinic
MD Anderson Cancer Center
MedCom
MediBeacon
MediGene
Medinova
Medipal Holdings
Medison Pharma
Medline Industries
Medpace
Medtronic
Meiji Seika
Melinta Therapeutics
Memorial Sloan Kettering Cancer Center
Menarini
Merck Sharpe & Dohme
Metabolon
Metamark Genetics
Methuselah Foundation
MicrobeDx
Minnesota Medical
Mironid
Mission Pharmacal
Mitobridge
Mitsubishi Tanabe Pharma
Murdoch Childrens Research Institute
NacuGen Therapeutics
Nashville Biosciences
National Institute of Allergy and Infectious Diseases
National Institute of Child Health and Human Development
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
National Kidney Registry
NCPC GeneTech
NephCure Kidney International
Nephrogenex
Nephros
Neptune Technologies & Bioressources
Nestle Health Science
NeuralStem
New York University School of Medicine
Nikkiso
Norgenix Pharmaceuticals
Noventure
Novo Nordisk
Nxstage Medical
OPKO Health
Organovo
Ortho-Clinical Diagnostics
Otsuka
Outpost Medicine
Oxford Immunotec
Palette Life Sciences
Pansend
Par Pharmaceutical
Patheon N.V.
Perlara
Pfizer
Phadia
Pharmacological research Institute Mario Negri
PharmaSwiss
Pharmstandard
Phosphate Therapeutics
Pierre Fabre
Piramal
PlugMed
Poiesis Medical
PPD
Precision Image Analysis
Premier Inc
Procept BioRobotics
Promepla
Promethera Biosciences
Prometic Life Sciences
Proteomics International
Purdue Pharma
PX Therapeutics
Q BioMed
Quebec Urological Association Foundation
Quimica Europea
Rambam Medical Center
RaNA Therapeutics
Rebiotix
Recordati
Recordati Espana
ReCor Medical
Relief Therapeutics
RenalSense
RenalytixAI
Renovar
RENX AI Labs
Resverlogix
Retrophin
RFSU
Rising Pharmaceuticals
Rockwell Medical
ROi (Resource Optimization & Innovation)
Roivant Sciences
Sanofi
Satellite Healthcare
Scanwell Health
Scohia Pharma
Shenzhen Hepalink Pharmaceutical
Shenzhen University
Shionogi
Shire Laboratories
Siemens Healthineers
Sinovant Sciences
SOM Biotech
Sonacare Medical
South Coast Specialty Compounding
Specialty Renal Products
Sphingotec
Stanford University
Stem Cell Network
Stryker
Swedish Orphan Biovitrum
Symic Biomedical
Syneron
Takeda Pharmaceutical
TARIS Biomedical
Teijin
TekMed
Teleflex
The Medicines Company
toSense
Tufts Medical Center
Tulane University
twoXAR
Unilife
UniQuest
United Medical Systems (UMS)
University of Bristol
University of California
San Diego
University of California Los Angeles
University of Cambridge
University of Michigan
University of Sheffield
University of South Carolina
University of South Carolina Research Foundation
Urigen
UroGen Pharma
Urovant Sciences
USMD Holdings
Vanderbilt University
Variant Pharmaceuticals
VenatoRx
Vifor-Fresenius Medical Care Renal Pharma Ltd
Vifor Pharma
Viracor-IBT
ViveBio
Vivione Biosciences
Vizient
Womens Choice Pharmaceuticals
Wuxi Apptec Laboratory Services
Xisle Pharma Ventures Trust
Xortx Pharma
Yale University
Yung Shin Pharm
Zenalux Biomedical
Zenyaku Kogyo

For more information about this report visit https://www.researchandmarkets.com/r/igrv9h

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets